Validation of an ocular microdialysis technique in rabbits with permanently implanted vitreous probes: systemic and intravitreal pharmacokinetics of fluorescein.
The purpose of this work is to validate a novel ocular microdialysis sampling technique in rabbits with permanently implanted vitreous probes. This objective is achieved by studying the vitreous pharmacokinetics of fluorescein following systemic and intravitreal administration. The rabbits were divided into two groups (groups I and II) based on whether or not they were allowed a recovery period following surgical implantation of probes. The integrity of the blood-retinal barrier was determined by the vitreal protein concentrations and the fluorescein permeability index. Vitreal protein concentrations returned to baseline 48 h after probe implantation and therefore experiments were conducted 72 h post-implantation of probes in rabbits where recovery period was allowed. The permeability indices for fluorescein after systemic administration in group I (without recovery period) and group II (with recovery period) indicated that the integrity of the blood-retinal barrier was maintained and were found out to be 0.55 +/- 0.27 and 0.71 +/- 0.38%, respectively, for the vitreous chamber. Following microdialysis probe implantation in the group II rabbits, the blood-retinal barrier integrity was not compromised. A novel microdialysis technique in rabbits with permanently implanted probes for studying the pharmacokinetics of posterior segment has been developed and characterized.
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 5005 Rockhill Road, 64110-2499, USA.
Banmeet S
BS
Anand
Harisha
H
Atluri
Ashim K
AK
Mitra
D000818:Animals; D001813:Blood-Retinal Barrier / Q000187:drug effects / Q000378:metabolism; D002408:Catheters, Indwelling / Q000639:trends*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005123:Eye / Q000187:drug effects / Q000378:metabolism; D019793:Fluorescein / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D007267:Injections / Q000379:methods; D008297:Male; D017551:Microdialysis / Q000379:methods*; D023421:Models, Animal; D011182:Postoperative Care / Q000379:methods; D011817:Rabbits; D013997:Time Factors; D014822:Vitreous Body / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism
D019793:Fluorescein